"The US Food and Drug Administration (FDA) has approved the tumor necrosis factor inhibitor adalimumab (Humira, AbbVie) for the treatment of moderate to severe hidradenitis suppurativa (HS), making it the first and only FDA-approved therapy"...
Ecoza Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Ecoza (econazole nitrate) Topical Foam is an azole antifungal used to treat a fungal infection of the feet, commonly called athlete's foot (interdigital tinea pedis) caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Common side effects of Ecoza Topical Foam include application site reactions such as burning, stinging, itching, or redness of the skin.
Each gram of Ecoza topical foam, 1%, contains a dose of 10 mg of econazole nitrate, which is applied to cover the affected areas once daily for 4 weeks. Ecoza may interact with warfarin. Tell your doctor all medications and supplements you use. During pregnancy, Ecoza should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Ecoza (econazole nitrate) Topical Foam Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Ecoza FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Ecoza topical foam or vehicle (246 subjects were exposed to Ecoza topical foam, 1% and 249 were exposed to vehicle). Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms.
Read the entire FDA prescribing information for Ecoza (Econazole Nitrate Topical Foam, 1%)
Additional Ecoza Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.